Zhejiang TV Station's New Space-time Report on Zhejiang —— Entering Zhejiang Deforensi Biotechnology Co., Ltd.

Innovation is the first driving force to lead development, and science and technology is a powerful weapon to overcome difficulties. At present, all kinds of high-tech enterprises in our province, while enhancing the "hard core" ability of science and technology, adhere to technological leadership and independent innovation, and constantly carry out technological research. Zhejiang difurunsi biotechnology co., ltd is one of them.

Recently, the 9th China Innovation and Entrepreneurship Competition (Zhejiang Division) won the first prize for the project "Development and Application of Genetically Engineered Vaccine" of Defoe Runce Biotechnology after the preliminary competition, semi-finals, finals and finals in Zhejiang Province.

Zhejiang Defoe Runsi Biotechnology Co., Ltd. was established on 20 17 1 1. Is a world-class recombinant virus vaccine research and development platform technology company, focusing on the research and development of virus vectors, genetic engineering vaccines for major infectious diseases of humans and animals, and the source of diagnostic technology.

Defoe Runce's R&D team consists of many people who have developed in medical, biochemistry, molecular biology and other professional and technical fields and have rich product development experience in the industry. The talent structure is high and the personnel allocation is reasonable. It is a scientific research team with doctor as the core, with strong innovation ability, long-term research and development of recombinant virus vaccine and rich R&D experience.

Defocus has a world-class platform for the construction and transformation of genetic engineering vaccines against various RNA and DNA viruses. The company's main business includes recombinant Newcastle disease vector COVID-19 vaccine, DIVA avian influenza vaccine, isothermal visual nucleic acid detection kit and pet third-party detection services.

Dr. Song Jiasheng, founder of Zhejiang Defoe Runsi Biotechnology Co., Ltd. said: "First of all, for the first project, our COVID-19 vaccine, a Newcastle disease virus vector, is actually very distinctive. Why do you say that? It can be inoculated mainly through nasal cavity, because this inoculation route can produce mucosal immunity locally. Generally speaking, it can prevent the local infection of the virus in the initial part. It has a very strong effect on local infection, and its practical social significance has a very great effect on blocking the spread of the virus. Second, we distinguish between avian influenza projects in infected animals and those in immunized animals. The main problem to be solved in this project is that many animals may be virus carriers after we are vaccinated, but these carriers will enter the circulation of food, so our vaccine can prevent these diseases, and at the same time, these potential carriers can be excluded by the simplest immunological method, thus ensuring that our people can eat this consumer product without being threatened by bird flu. "

At present, defocusing has successfully developed the world's first inactivated avian influenza virus vaccine to distinguish infected and immunized animals. The popularization of this technology is expected to eliminate the great harm of avian influenza represented by H7N9 to food safety and public health. Its core technology has applied for 3 national invention patents and 3 PCT patents. In 2020, the world's first COVID-19 vaccine candidate strain of recombinant Newcastle disease vector (NDV) was developed, and COVID-19 antibody was successfully induced in mice. This is an aerosol nasal vaccine, which is a supplement to the injection vaccine.

Dr. Song Jiasheng, founder of Zhejiang Defoe Runsi Biotechnology Co., Ltd. said: "The core competitiveness of our company is actually mainly in the cross field of molecular biology and virology, that is, some molecular virology we are doing now. The technology of these vaccines I am talking about is that we can transform some of our vaccine strains through genetic modification, and then make them adapt to the characteristics we need in vaccinology. As for Newcastle disease vaccine, COVID-19 vaccine is actually the fastest in the world. In fact, on April 26, 2020, we initially completed the mouse experiment. What about the differential vaccine for avian influenza? It is actually the first technology in the world. We have applied for invention patents in three countries and we have authorized these patents. We have applied for international patents in Europe, America and nine countries along the Belt and Road, and now we have entered.

In an enterprise, the core culture of the team is particularly important. It is a banner of the enterprise, which determines the life of the enterprise. A good culture can unite and integrate various forces of an enterprise, form a strong cohesive force within the enterprise, and then turn it into a great driving force for the development of the enterprise.

Dr. Song Jiasheng, founder of Zhejiang Defoe Runsi Biotechnology Co., Ltd. said: Our team, at present, everyone's cooperation is also very good. The purpose of starting a business is to contribute to society. This is our unchanging initial intention. There are two sentences in our company. The first sentence is to create differences for the world, and the second sentence is to create platforms for employees.

Project supported by Defoe Rose 20 17 Hangzhou High-tech Zone (Binjiang) Overseas High-level Talents "5050" Program. 20 18 was selected as the storage enterprise of Hangzhou science and technology start-up enterprise cultivation project (Young Eagle Project); 20 19 was recognized as a small and medium-sized science and technology enterprise in Zhejiang province; In 2020, it was recognized as a national high-tech enterprise and a national science and technology small and medium-sized enterprise.

Looking back, inspiring people; Looking ahead, there is a long way to go. In the future, Defoe Runce will, as always, be proactive, innovative, professional and brand-oriented, stand at a higher point in the industry and strive to build a top brand in the industry.

This program was broadcast on February 2 1 on Zhejiang Education Film and Television Channel.

Guangtongshe-Zhejiang Xinshi Culture Media Co., Ltd. (Editor: Wang Fei | Director: Diligence)